AU2001216580A1 - Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects - Google Patents

Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects

Info

Publication number
AU2001216580A1
AU2001216580A1 AU2001216580A AU1658001A AU2001216580A1 AU 2001216580 A1 AU2001216580 A1 AU 2001216580A1 AU 2001216580 A AU2001216580 A AU 2001216580A AU 1658001 A AU1658001 A AU 1658001A AU 2001216580 A1 AU2001216580 A1 AU 2001216580A1
Authority
AU
Australia
Prior art keywords
aldosterone
prophylaxis
epoxy
treatment
pathogenic effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001216580A
Inventor
Kenton N. Fedde
John W. Funder
Susan M. Garthwaite
Ricardo Rocha
Barbara Roniker
Gordon H. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2001216580A1 publication Critical patent/AU2001216580A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AU2001216580A 2000-06-13 2000-11-14 Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects Abandoned AU2001216580A1 (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US21125300P 2000-06-13 2000-06-13
US21145900P 2000-06-13 2000-06-13
US21131100P 2000-06-13 2000-06-13
US21106400P 2000-06-13 2000-06-13
US21145100P 2000-06-13 2000-06-13
US21126400P 2000-06-13 2000-06-13
US21125000P 2000-06-13 2000-06-13
US21134000P 2000-06-13 2000-06-13
US60211340 2000-06-13
US60211311 2000-06-13
US60211253 2000-06-13
US60211250 2000-06-13
US60211459 2000-06-13
US60211451 2000-06-13
US60211264 2000-06-13
US60211064 2000-06-13
US22135800P 2000-07-27 2000-07-27
US22136400P 2000-07-27 2000-07-27
US60221364 2000-07-27
US60221358 2000-07-27
US23305600P 2000-09-14 2000-09-14
US60233056 2000-09-14
PCT/US2000/031263 WO2001095893A1 (en) 2000-06-13 2000-11-14 Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects

Publications (1)

Publication Number Publication Date
AU2001216580A1 true AU2001216580A1 (en) 2001-12-24

Family

ID=27582731

Family Applications (3)

Application Number Title Priority Date Filing Date
AU1604001A Pending AU1604001A (en) 2000-06-13 2000-11-01 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
AU2001216040A Ceased AU2001216040B2 (en) 2000-06-13 2000-11-14 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
AU2001216580A Abandoned AU2001216580A1 (en) 2000-06-13 2000-11-14 Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU1604001A Pending AU1604001A (en) 2000-06-13 2000-11-01 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
AU2001216040A Ceased AU2001216040B2 (en) 2000-06-13 2000-11-14 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects

Country Status (12)

Country Link
EP (1) EP1289507B1 (en)
JP (1) JP2004503495A (en)
KR (1) KR20030010716A (en)
CN (1) CN1236763C (en)
AR (2) AR029134A1 (en)
AT (1) ATE385789T1 (en)
AU (3) AU1604001A (en)
CA (1) CA2407699A1 (en)
HK (1) HK1060065A1 (en)
MX (1) MXPA02012257A (en)
PE (2) PE20020173A1 (en)
WO (2) WO2001095892A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518611A (en) * 2000-07-27 2004-06-24 ファルマシア・コーポレーション Aldosterone blocker therapy to prevent or treat inflammation-related disorders
CA2469616A1 (en) * 2001-12-12 2003-06-19 James W. Aiken Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
WO2003051372A1 (en) * 2001-12-13 2003-06-26 Pharmacia Corporation Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
WO2003080068A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
JP2005536536A (en) * 2002-08-23 2005-12-02 ファルマシア コーポレイション Modulation of matrix metalloproteinase (MMP) activity by aldosterone blockers
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
ES2338781T3 (en) * 2002-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft USE OF DROSPIRENONE FOR THE TREATMENT OF HYPERTENSION.
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
DE102011012712A1 (en) * 2011-03-01 2012-09-06 Frank Lehmann-Horn Use of aldosterone receptor antagonists for the treatment of female sexual dysfunction
US20230048130A1 (en) * 2020-01-21 2023-02-16 University Of Southern California Ketogenic fasting-mimicking diet to improve kidney function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (en) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-SPIROXANER OCH ANALOGER, SOM INNEHAOLLER EN OEPPEN RING E, FOERFARANDE FOER DERAS FRAMSTAELLNING SAMT DESSA INNEHAOLLANDE PHARMACEUTICAL PREPARATION.
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
US6410524B1 (en) * 1998-11-06 2002-06-25 G. D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease

Also Published As

Publication number Publication date
PE20020173A1 (en) 2002-03-14
CN1455667A (en) 2003-11-12
AU1604001A (en) 2001-12-24
AR029680A1 (en) 2003-07-10
MXPA02012257A (en) 2005-04-19
AU2001216040B2 (en) 2006-06-15
KR20030010716A (en) 2003-02-05
WO2001095893A1 (en) 2001-12-20
ATE385789T1 (en) 2008-03-15
AR029134A1 (en) 2003-06-04
EP1289507B1 (en) 2008-02-13
PE20011341A1 (en) 2002-02-06
JP2004503495A (en) 2004-02-05
EP1289507A1 (en) 2003-03-12
WO2001095892A1 (en) 2001-12-20
HK1060065A1 (en) 2004-07-30
CA2407699A1 (en) 2001-12-20
CN1236763C (en) 2006-01-18

Similar Documents

Publication Publication Date Title
ZA200507996B (en) Use of an IBAT inhibitor for the treatment or prophylaxis of constipation
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU2001272852A1 (en) Composition for the treatment of migraine
AU2001271567A1 (en) Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
AU2001233081A1 (en) Composition for treatment of stress
AU2002327284A1 (en) Use of cyclic heptapeptides for the inhibition of biofilm formation
AU2001216580A1 (en) Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
AU2001285156A1 (en) Combination therapy for the treatment of migraine
AU2001239301A1 (en) Use of ectoin or ectoin derivatives for the prophylaxis and/or treatment of uv-induced immunosuppression
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2000231423A1 (en) Specific therapeutic composition for treating aids
PT1698338E (en) S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
AU2001255580A1 (en) Methods and compositions for the diagnosis of schizophrenia
AU2002221566A1 (en) Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
AU2001287560A1 (en) Agent for inhibiting adhesion of the pathogenic flora of the skin
AU2003238414A1 (en) Use of diuretics for treating swellings
AU2000272704A1 (en) Use of compounds for the treatment of obesity
PL370853A1 (en) Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2335601A (en) Treatment or prevention of diarrhea